Trial Profile
Efficacy study of HP749, 20mg versus placebo in patients with OAB-UG058-0204 (Over active bladders).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Besipirdine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms UG058-0204
- 12 Aug 2011 New trial record